Table 3 Comparison of adverse effects between two treatments types with intravesical bacillus Calmette–Guérin
ALL (n = 78) | Induction (n = 40) | Maintenance (n = 38) | P value | |
|---|---|---|---|---|
Adverse effects (%) | ||||
Grade ≤ 2/Grade ≥ 3 | 39 (50.0)/0 | 13 (32.5)/0 | 26 (68.4)/0 | 0.003 |
Local | 30 (38.6) | 9 (22.5) | 21 (57.9) | 0.003 |
Systemic | 16 (20.5) | 7 (17.5) | 9 (23.7) | 0.50 |
Both | 7 (9.0) | 3 (7.5) | 4 (10.5) | 0.64 |
Local symptoms (%) | ||||
Miction pain | 18 (23.1) | 4 (10.0) | 14 (36.8) | < 0.001 |
Pollakiuria | 8 (10.3) | 3 (7.5) | 5 (13.2) | 0.41 |
Hematuria | 6 (7.7) | 1 (2.5) | 5 (13.2) | 0.10 |
Residual urine | 2 (2.6) | 0 | 2 (5.3) | 0.23 |
Urgent urination | 1 (1.3) | 1 (2.5) | 0 | 0.33 |
Systemic symptoms (%) | ||||
Arthralgia | 1 (1.3) | 1 (2.5) | 0 | 0.33 |
Fever | 15 (19.2) | 6 (15.0) | 9 (23.7) | 0.40 |
Rash | 1 (1.3) | 1 (2.5) | 0 | 0.33 |